04.04.2017 • TopicsDr. Gerd BergmannNordmannNRC

Open to New Ways of Doing Business

Christopher Erbslöh, managing director, C.H. Erbsloeh
Christopher Erbslöh, managing director, C.H. Erbsloeh

“Today’s digital transformation debate bewilders me somewhat, as this is not a new topic but one that has been around for more than 40 years. The only difference is the speed at which new and updated technology is available. Today, as back in the 1970s, the only right answer to the digital transformation debate is: “Yes, we should introduce and use any new technology that advances our business at a justifiable cost.”

For specialty distributors like C.H. Erbslöh we expect positive effects from new technologies mainly in administrative processes but also in the supply chain. We, however, neither see our workforce being reduced nor a full transformation of our point of sales to an e-commerce platform in the next 5 to 8 years. Having said that, it is obvious that some product categories surely will be sold through e-commerce platforms in the near future. Still, we do not have a special digital agenda as new ideas, technologies and ways of doing business always have been on our agenda.”

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
19.03.2025 • TopicsStrategy

Substances of Concern

The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.